Intellia Therapeutics (NASDAQ:NTLA) Shares Down 8.3% – What’s Next?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) fell 8.3% on Tuesday. The stock traded as low as $11.08 and last traded at $11.11. Approximately 1,127,780 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 5,103,586 shares. The stock had previously closed at $12.11.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $25 price target, signaling continued confidence despite lowering its earnings forecasts.
• Neutral Sentiment: Intellia reported inducement grants under Nasdaq listing rules; the provided report does not specify their size or likely financial impact. Intellia Therapeutics reports inducement grants
• Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS estimates, including its FY2026 forecast to a loss of $3.24 per share from $3.06 and its FY2027 forecast to a loss of $3.17 from $3.12. It also reduced estimates for several 2027 quarters.
• Negative Sentiment: Brookline Capital Markets cut its FY2026 estimate to a loss of $2.92 per share and lowered its longer-term profit forecasts for 2029 and 2030, tempering expectations for future earnings growth.
• Negative Sentiment: The company’s latest reported quarter also missed analyst expectations for both EPS and revenue; revenue fell 47.8% year over year. These results add to the concerns reflected in the forecast cuts.

Wall Street Analyst Weigh In

NTLA has been the subject of a number of recent analyst reports. Wedbush upped their target price on Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. Evercore upgraded Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target on the stock in a research report on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. Barclays initiated coverage on Intellia Therapeutics in a report on Tuesday, October 6th. They issued an “underweight” rating and a $8.00 price objective for the company. Finally, Wall Street Zen lowered Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics presently has an average rating of “Hold” and an average target price of $21.44.

Intellia Therapeutics Stock Down 7.5%

The company’s fifty day moving average price is $12.08 and its 200-day moving average price is $13.04. The stock has a market capitalization of $1.57 billion, a PE ratio of -3.34 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $9.74 million. During the same quarter in the previous year, the company earned ($0.92) EPS. The business’s quarterly revenue was down 47.8% on a year-over-year basis. Equities research analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In other news, CEO John M. Leonard sold 9,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total value of $107,910.00. Following the sale, the chief executive officer directly owned 1,138,064 shares of the company’s stock, valued at approximately $13,645,387.36. This represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of NTLA. Bank of America Corp DE raised its position in Intellia Therapeutics by 11.2% in the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after buying an additional 139,325 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Intellia Therapeutics by 1,082.1% during the 1st quarter. Royal Bank of Canada now owns 465,499 shares of the company’s stock valued at $5,968,000 after acquiring an additional 426,121 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Intellia Therapeutics during the 2nd quarter valued at about $1,595,000. Assenagon Asset Management S.A. purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at about $3,875,000. Finally, BlackRock Inc. bought a new stake in shares of Intellia Therapeutics in the second quarter worth approximately $260,721,000. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.